Pluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that...
Friday, August 17, 2012, 9:34 AM ETPluristem Therapeutics (PSTI +4.2%) enjoys continued upward momentum after Thursday's news that it received permission from India's health ministry to proceed with a Phase II clinical trial for the treatment of Buerger's disease. The trial could be followed by a larger multi-national Phase III. Shares popped 10% yesterday on the announcement.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles